OE-MRI for PAtients with Lung cancer (OPAL study)

Oxygen-enhanced magnetic resonance imaging (OE-MRI) for patients with lung cancer receiving chemoradiation

Tumour hypoxia is associated with poor survival in non-small cell lung cancer patients (NSCLC). Therefore, there is an urgent unmet need to develop non-invasive biomarkers that can detect and track changes in tumour hypoxia. Imaging biomarkers are attractive as candidates for the assessment of tumour hypoxia due to limited tissue material in radiotherapy-treated NSCLC patients.

Recently, a clinical first-in-human study, led by Professor James O’Connor at University of Manchester, demonstrated that oxygen-enhanced MRI (OE-MRI) biomarkers can be used to detect tumour hypoxia and monitor changes in hypoxia in response to treatment. 1  

The NCITA Exemplar 5 OPAL study will determine the feasability of OE-MRI across different platforms and field strengths as well as multicentre repeatability of OE-MRI biomarkers. Recently, the group have reported the feasibility, repeatability and reproducibility of a dynamic T2*-sensitised OE-MRI protocol for dynamic OE-MRI of the lung in healthy volunteers. 2

The role of OE-MRI in adaptive radiotherapy planning in non-small cell lung cancer patients will also be determined. These studies are centred at The University of Manchester and University College London, before being opened up to other sites.

NCITA Exemplar 5